Summary Natural killer (NK) cells are involved in the antitumoral immunologic mechanism. These cells act through the release of cytotoxic molecules defined as NK cytotoxic factors (NKCF). Inhibitory factors of NK and NKCF mediated lysis have been described in in vitro assays. This study evaluates the induction of resistance to NKCF cytotoxicity by sera from 27 patients with colon, breast and lung cancer. Addition of these sera to the cytolytic assay where K562 cells and concentrated NKCF were used, induced resistance to NKCF mediated cytotoxicity in 21 cases (77%). The sera from the group with metastasis blocked NKCF lysis more markedly than the group with local tumours. However, no differences were observed when the groups with colon, breast and lung cancers were compared. This blocking effect was not found to be related to gamma interferon (IFN) levels. In a previous study, we described a tumour factor (NK-RIF) produced by human cell lines derived from metastatic adenocarcinomas. This factor blocked lysis of tumour target cells by NK cells. Consequently, it is proposed that the release of similar tumour factors with a capacity to induce resistance to NKCF may be involved in tumour growth and metastatic spreading in in vivo.
Natural killer (NK) cells have been implicated in the control of distant metastatic diseases (Herberman & Holden, 1978; Trinchieri & Perussia, 1984) . They have been defined as a subset of peripheral blood lymphocytes with distinctive morphological, phenotypic and functional characteristics. NK cells display the structural features of large granular lymphocytes (LGL) (Grossi et al., 1978 (Grossi et al., , 1982 Saksela et al., 1979; Timonen et al., 1981) and the ability to lyse a variety of neoplastic and non-neoplastic target cells, including virusinfected ones and hematopoietic precursors (Herberman et al., 1982 (Herberman et al., , 1986 Trinchieri & Perussia, 1984) . NK cells from human, rat or mouse, release natural killer cytotoxic factors (NKCF), functionally defined as lymphokines selectively cytotoxic for NK target cells (Herberman et al., 1979 (Herberman et al., , 1986 Savary & Lotzova, 1986) .
The mechanisms involved in the resistance or susceptibility of tumour cells to NK cells are poorly understood (Stern et al., 1980; Powel et al., 1987; Harris et al., 1987; Pefia et al., 1990a,b) , but studies have demonstrated that natural killer cell activity is diminished in colon, breast and lung cancer, especially in advanced stages or in those with metastatic processes (Lin et al., 1987; Tartter et al., 1987; Hisamatus et al., 1986) . Thus, the deficient activity of NK cells results in increased numbers of metastasic deposits and tumoral escape from immunologic vigilance (Schantz et al., 1986 ).
We have recently described a factor (NK-RIF) released by cell lines with adenocarcinoma metastasis and which induces resistance of K562 cells to NK mediated lysis by blockage of NKCF activity without affecting target and effector conjugate formation Solana et al., 1990a,b Each sample was tested in three independent experiments and variations never exceeded 15% inhibition.
Determination ofgamma interferon levels The IFN levels were determined by a two-site immunoradiometric assay -IRMA (Sucrosep Boots-celltech diagnostic limited, Berkshire, UK). Concentrations were quantified directly by incubation with an '251I-labelled antibody complex which was then immobilised by incubation with a sheep anti-aIFN antibody coupled to the solid phase. In our experimental conditions the assay had a minimum sensitivity of Figure 1 Mean ± s.e.m. of the inhibitory intensity of NKCF mediated cytotoxicity by sera from patients with (n = l1) or without mestatasis (n = 5). The difference between the two groups is significant according to Student t-test. respectively, demonstrating that the site of the primary disease is not the main factor determining the capacity of these sera to inhibit NKCF cytotoxicity (Table II) .
The blockage effect to NKCF cannot be attributed to aIFN As previously reported, treatment with aIFN can also induce resistance to NKCF lysis, thus, we also measured aIFN levels in sera from these patients. Most of them (24/27) had detectable levels of interferon while it was not detectable in controls (Table IV) . We suggest that the high levels of serum interferon in these subjects is a consequence of the immunologic response of the host organism to neoplasm. However, NKCF blockage cannot be attributed to the presence of IFN, as it appears in all the stages of the disease regardless of the induction of resistance to NKCF cytolysis.
Discussion
Several hypothesis explaining NK resistance of different tumour cells have been suggested. These include, for example, a defect in the recognition of target cells with a relationship between HLA antigen expression and tumour cell performance (Stern et al., 1980; Karre et al., 1986; Powel et al., 1987; Rodger et al., 1988; Alonso et al., 1989; Ljnggren & Karre, 1990; Solana et al., 1990b; Peiia et al., 1990a,b) ; a resistance of target cells to lytic factors such as TNF or NKCF produced by immunocompetent cells (Roozemond et al., 1987) ; or an inhibited NK activity owing to tumour suppressor factors or peptides such as prostaglandin E2 and NK-RIF (Harris et al., 1987; Serrano et al., 1989 Serrano et al., , 1990 Solana et al., 1990a) . However, the exact mechanisms by which NK cells interact with target cells remains unclear. The different roles that the molecules play on the target cell surface such as recognition elements by NK effectors have been postulated (Vodilenich et al., 1983; Hercend et al., 1984; Natuk & Welsh, 1987; Johnson et al., 1987) .
Many authors have reported diminished NK activity in different experimental models and in patients with tumours with different stages of the disease (Hisamatsu et al., 1986; Schantz et al., 1986; Wei & Heppner, 1987; Lin et al., 1987; Tartter et al., 1987) . Cells from freshly explanted solid tumours are resistant to NK mediated lysis and the causes determining NK resistance are not clearly understood.
The presence of factors in sera from tumours patients inhibiting NK cytotoxicity has been described, although results are not conclusive (our unpublished results; Brenner et al., 1986) . This is probably due to the presence in this sera of a variety of factors such as aIFN which has a dual effect on NK lysis, either activating NK cells (Herberman et al., 1986) or inducing NK resistance in several target cells (Ramirez et al., 1990) . Thus, in order to find an experimental system where only the inducation of resistance to lysis is evaluated, we studied the capacity of sera from tumour patients to block lysis of K562 cells by concentrated NKCF.
The analysis of 27 sera from patients with colon, breast and lung cancer demonstrated that 10/11 from metatatic and 2/5 from local disease had the capacity to block NKCF mediated cytotoxicity of NK target cell line K562. This capacity was not related to the stage of the disease, but only to the presence of the metastasis.
Although a number of tumour factors have been defined to inhibit NK cell activity, the induction of NK resistance has been related mainly to the activity aIFN and a new tumour growth factor, released in vitro by tumour cell lines from metastatic adenocarcinomas, defined as NK-RIF (NK-resistance inducing factor). Both make K562 cells resistant to NK and NKCF lysis. Moreover, NK-RIF does not affect LAK, macrophage and T cells mediated cytotoxicity nor conjugate formation between the NK effector and target cells (Serrano et al., , 1990 Solana et al., 1990a,b) .
Other proteins such as x2-macroglobulin or non-specific proteases may also participate in the blockage observed by neutralising with NK cytotoxic factors before they can lyse the target cells as they interact with other lymphokines (James, 1990) .
When we studied the presence of aIFN in these patients, our results showed high levels of aIFN in most of them. No significant relationship between aIFN levels and the degree of NKCF lysis blockage were found, suggesting that it is not the main agent responsible for the induction of NKCF resistance.
In conclusion, although further studies on the molecular definition of this activity are required, the data presented show that sera from patients with metastatic cancers induce resistance to K562 to NKCF lysis and suggest that molecules that induce NK resistance can be produced in vivo by metastatic neoplasm cells. These results prompt the possibility that the release of NK-RIF like factors facilitate tumour growth and the spread of neoplasm, allowing tumour cells to evade the host resistance mechanisms. Investigations leading to the understanding of the mechanisms involved in NK resistance induced by tumours factors will lead to a better II   40  7  IV  53  4  D  60  5  III  65  23  IV  49  9  D  64  14  III  47  11  D  43  16  III  60  12  D  44  22  III  38  20  D  52  1  IV  61  25  D  39  2  IV   -6  IV  47  8  IV   - non-detectable level. Measured in U ml-'.
knowledge of the NK-tumour cell interaction and will contribute to a better evaluation of the diagnosis and prognosis of cancer patients.
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